Holen Sie sich die Stockscreener-App
762.94
0.14%
1.09
Regeneron Pharmaceuticals Inc Aktie (REGN) Neueste Nachrichten
FDA approves expanded EYLEA HD dosing intervals - Eyes On Eyecare
Trump Imposes 100% Drug Tariffs: 5 Pharma Stocks That Won’t Pay a Dime - Investing.com
All You Need to Know About Regeneron (REGN) Rating Upgrade to Buy - Yahoo Finance
Tritonpoint Wealth LLC Sells 1,938 Shares of Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron Pharmaceuticals, Inc. $REGN Shares Sold by Sovran Advisors LLC - MarketBeat
Regeneron’s EYLEA HD Label Update Shifts Retinal Care And Competition - simplywall.st
Regeneron Pharma (REGN) shares up after Jim Cramer called it a good stock - MSN
REGN Financials: Revenue Breakdown, Margins & Competitor Comparison - Intellectia AI
Regeneron Pharmaceuticals Inc (REGN) SEC filings - GuruFocus
Regeneron Pharmaceuticals Inc (REGN) Stock Forecast, Price Targets and Analysts Predictions - gurufocus.com
Allspring Global Investments Boosts Stake in Regeneron Pharmaceuticals - National Today
Regeneron Pharmaceuticals, Inc. $REGN Shares Bought by Allspring Global Investments Holdings LLC - MarketBeat
Where is Regeneron Pharmaceuticals (REGN) headed according to analysts? - MSN
Arthur Ryan Sells Shares of Regeneron Pharmaceuticals Inc - GuruFocus
Regeneron (REGN) director Ryan sells $77,727 in stock By Investing.com - Investing.com South Africa
Regeneron Pharmaceuticals Inc (RGO.DU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Regeneron (REGN) director Ryan sells $77,727 in stock - Investing.com
Small Rule 10b5-1 sale by Regeneron (REGN) director Arthur F. Ryan - Stock Titan
Best Pharmaceutical Stocks To Follow TodayApril 3rd - MarketBeat
Will Regeneron (REGN) Beat Estimates Again in Its Next Earnings Report? - Yahoo Finance Australia
Regeneron Secures Two FDA Approvals in One Day: Does the Math Support an Above $1,200 Target? - TIKR.com
Regeneron Pharmaceuticals: The Scientific Juggernaut Navigating a High-Stakes Transformation - FinancialContent
The Bull Case For Regeneron (REGN) Could Change Following New Dupixent BP Approval In JapanLearn Why - simplywall.st
Aberdeen Group Boosts Regeneron Pharmaceuticals Holdings - National Today
Aberdeen Group plc Has $124.84 Million Holdings in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
FDA Approves Extension of Dosing Intervals for Regeneron's Eylea HD - VisionMonday.com
Hims & Hers Health, Regeneron, Biogen, BioMarin Pharmaceutical, and Moderna Shares Are Falling, What You Need To Know - Yahoo Finance
FDA approves extended dosing for Regeneron’s EYLEA HD treatment By Investing.com - Investing.com Australia
Regeneron partners with TriNetX for health data access - investing.com
Regeneron Pharmaceuticals announced that, as part of their strategic partnership, the company will invest up to 200 million dollars in Trinetx. - Bitget
TriNetX Collaborates with Regeneron to Access De-Identified Electronic Health Records of 300 Million Patients to Drive Research and Product Development in Life Sciences and Digital Health Solutions - PR Newswire
Regeneron Pharmaceuticals, Inc. (REGN34.SA) company profile and facts - Yahoo Finance Singapore
Regeneron says it expects to avoid new US pharma tariffs - Reuters
FDA Expands Dosing Flexibility for Regeneron's EYLEA HD - GuruFocus
FDA approves extended dosing for Regeneron’s EYLEA HD treatment - investing.com
FDA lets some EYLEA HD patients cut eye injections to 2 or 3 a year - Stock Titan
Ophthalmology Drugs Market: Current Landscape and Future Outlook - Barchart
Wells Fargo Maintains Regeneron Pharmaceuticals(REGN.US) With Hold Rating, Maintains Target Price $825 - Moomoo
Moody Lynn & Lieberson LLC Purchases New Position in Regeneron Pharmaceuticals, Inc. $REGN - MarketBeat
Regeneron’s Cat Allergy Blocker is Back and Reducing Itchy Eyes - Allergic Living
Here’s what analysts are saying about Regeneron Pharmaceuticals (REGN) - MSN
AVIP BlackRock Balanced Allocation Portfolio's Regeneron Pharmaceuticals Inc(REGN) Holding History - GuruFocus
Regeneron Pharmaceuticals Inc. stock outperforms competitors on strong trading day - marketwatch.com
BMO Autocallable Notes Linked to Regeneron (NASDAQ: REGN) — US$270K - Stock Titan
A Look At Regeneron Pharmaceuticals (REGN) Valuation After Japan’s Approval Of Dupixent For Bullous Pemphigoid - Yahoo Finance
Bayer Wins EC Approval to Expand Kerendia in Heart Failure Treatment - The Globe and Mail
Piper Sandler Rates Regeneron Pharmaceuticals (REGN) as Overweig - GuruFocus
Piper Sandler Rates Regeneron Pharmaceuticals (REGN) as Overweight | REGN Stock News - GuruFocus
Truist Securities Updates Regeneron Pharmaceuticals (REGN) Price Target | REGN Stock News - GuruFocus
Truist Financial Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price - MarketBeat
Regeneron a new overweight at Piper on Dupixent, pipeline - Seeking Alpha
Truist cuts Regeneron stock price target on biosimilar concerns - Investing.com
Regeneron Pharmaceuticals (NASDAQ:REGN) Now Covered by Analysts at Piper Sandler - MarketBeat
Piper Sandler initiates Regeneron stock with Overweight rating - investing.com
Is It Time To Reassess Regeneron (REGN) After Its Mixed Share Price Performance? - simplywall.st
Regeneron stock gets a new roadmap investors can track in 2026 - MSN
Regeneron Pharmaceuticals: A Strong Contender in the Biotech Arena - theglobeandmail.com
0.00%
0.93%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):